Evidence map›Paper›PMID 22314182›Full record

ReviewLancet (London, England)2012

Chronic obstructive pulmonary disease.

Marc Decramer, Wim Janssens, Marc Miravitlles

3 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Lancet (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 493 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
493citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02946658 phase1 / phase2suspendednot on this mapstarted 2016, after this paper: background citation

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Chronic Lung Disorders

TypeinterventionalSponsorHealeon Medical IncRan2016 to 2027Enrolled100ConditionsLung DiseaseArmslipoaspiration, ADcSVF, Normal Saline IV
NCT03909750 phase1suspendednot on this mapstarted 2019, after this paper: background citation

Use of Autologous Stem/Stromal Cells in Chronic Lung Disorders: Obstructive (COPD) and Restrictive (RLD)

TypeinterventionalSponsorHealeon Medical IncRan2019 to 2026Enrolled50ConditionsCOPD, Respiratory InsufficiencyArmsLipoaspiration, AD-cSVF, Normal Saline IV
NCT04757714 nawithdrawnnot on this mapstarted 2023, after this paper: background citation

Thoracic Kyphosis and Osteoporosis: Study of Their Relationship With Respiratory Functions in Chronic Obstructive Pulmonary Disease.

TypeinterventionalSponsorCentre Hospitalier Régional d'OrléansRan2023 to 2025Enrolled0ConditionsCOPD, Osteoporosis, KyphosisArmsThe high-resolution peripheral scanner (HRpQCT) of the tibia and radius, a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system), Questionnaires, A search for sarcopenia by studying the strength of the grip (dynamometer)
3 · Its place in the literature

Who cites it

493 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

433 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marc DecramerRespiratory Division, University Hospital, University of Leuven, Leuven, Belgium. marc.decramer@uzleuven.be
Wim Janssens
Marc Miravitlles

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. The main cause is smoking tobacco, but other factors have been identified. Several pathobiological processes interact on a complex background of genetic determinants, lung growth, and environmental stimuli. The disease is further aggravated by exacerbations, particularly in patients with severe disease, up to 78% of which are due to bacterial infections, viral infections, or both. Comorbidities include ischaemic heart disease, diabetes, and lung cancer. Bronchodilators constitute the mainstay of treatment: β(2) agonists and long-acting anticholinergic agents are frequently used (the former often with inhaled corticosteroids). Besides improving symptoms, these treatments are also thought to lead to some degree of disease modification. Future research should be directed towards the development of agents that notably affect the course of disease.

Indexed as

Adrenal Cortex HormonesAirway RemodelingAnti-Bacterial AgentsBiomarkersBronchodilator AgentsClinical Trials as TopicComorbidityDrug Therapy, CombinationGenetic Predisposition to DiseaseHumansLung TransplantationOxidative StressPulmonary Disease, Chronic ObstructiveRespiratory Function TestsRespiratory TherapyRisk FactorsAdrenal Cortex HormonesAnti-Bacterial AgentsBiomarkersBronchodilator Agents

Identifiers

PMID22314182
PMCPMC7172377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.